Screened 2026-09-08 · the tape above runs as of 23:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its distribution label.
Regeneron Pharmaceuticals holds its Distribution at $810.31. Elevated stress, defensive posture warranted, held for 5 days.
As held on the ledger · 2026-09-08
Phase
Distribution · caution
Quantitative state
Elevated stress, defensive posture warranted, held for 5 days
Price at the screen
$810.31
Valuation
20.06 trailing · 13.37 forward price to earnings
Values screen
PASS· score 69.9
Beta
0.19
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
6.67%
Below 33%
Interest-bearing debt is just 6.7% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
25.30%
Below 33%
Cash held in interest-bearing accounts and securities is 25.3% of assets, under the one-third limit.
Pass
Receivables
21.84%
Below 49%
Money owed to the company is 21.8% of assets, under the 49% limit.
Pass
Revenue purity
5.00%
Below 5%
Only 5.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads OPPORTUNITY: it trades at roughly a 27% discount to our $1,030.00 fair value, moderate competitive moat, 16.70% revenue growth.
Fair value range in USD, drawn from the 2026-09-08 screen. The gold marker is the market price at the same screen. A 27.1% margin of safety to the base estimate.
Third-party analyst targets: 27 covering, consensus Buy. The average target sits +2% from the screen price.
Reading the gap · Our model sees value the Street hasn't fully caught up to yet.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-08 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Biotech Pipeline Delivers Steady Cash and Growth
A medicine that actually clears blocked vision or calms severe inflammation can shift from lab bench to patient in a few years and start paying back fast. Regeneron keeps turning that process into reliable revenue.
The company grows sales 19 percent a year, holds a 30 percent profit margin and trades at 12.4 times forward earnings. A moderate moat, clean ethical screen and 48 percent gap to our fair value mark it as an opportunity rather than a story stock.
Pipeline setbacks and fresh competition remain real threats in biotech, while 15 percent return on equity shows capital still works harder elsewhere. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
REGN trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 23.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (27 analysts) rates it buy, with a mean price target of $840.
2026-07-30Markup · changed$667.17+0.0%Entry 10
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (28 analysts) rates it buy, with a mean price target of $833. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-28Accumulation$667.17-1.4%Entry 9
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 1.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (28 analysts) rates it buy, with a mean price target of $833. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-27Accumulation$676.69+0.0%Entry 8
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (28 analysts) rates it buy, with a mean price target of $833. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-26Accumulation$676.69+0.0%Entry 7
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (28 analysts) rates it buy, with a mean price target of $833. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-25Accumulation$676.69+0.0%Entry 6
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (28 analysts) rates it buy, with a mean price target of $833. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-24Accumulation$676.69+0.0%Entry 5
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (28 analysts) rates it buy, with a mean price target of $833. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 6.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (28 analysts) rates it buy, with a mean price target of $833. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-18Distribution$635.45+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (28 analysts) rates it buy, with a mean price target of $833.
2026-07-03Distribution$635.45+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
